

PRESS RELEASE  
30 April 2012



## **New number of shares and votes in BioInvent International AB (publ)**

**Lund, Sweden – 30 April 2012** - BioInvent International AB (publ) (OMXS:BINV) today announced that the company's total number of shares as per 30 April 2012 amounts to 73,925,782 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the rights issue of 6,720,525 shares with preferential right for the company's shareholders that was announced on 14 February 2012.

--END--

### **To the editors:**

#### **About BioInvent**

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by n-CoDeR<sup>®</sup>, a proprietary antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

### **For further information, please contact:**

#### ***BioInvent International AB***

Svein Mathisen  
President & CEO  
Mobile: +46 (0)708 97 82 13  
E-mail: [svein.mathisen@bioinvent.com](mailto:svein.mathisen@bioinvent.com)

Sten Westerberg  
Vice President, Investor Relations  
Mobile: +46 (0)768 68 50 09  
E-mail: [sten.westerberg@bioinvent.com](mailto:sten.westerberg@bioinvent.com)

College Hill (media enquiries)  
Melanie Toyne Sewell, Anastasios Koutsos  
Tel: +44 (0)20 7866 7856  
Rebecca Skye Dietrich  
Phone: +1 (857) 241 0795  
E-mail: [bioinvent@collegehill.com](mailto:bioinvent@collegehill.com)

#### **BioInvent International AB (publ)**

Co. reg. No. 556537-7263,  
Visiting address: Sölvegatan 41  
Mailing address: SE-223 70 LUND



Phone: +46 (0)46 286 85 50

[info@bioinvent.com](mailto:info@bioinvent.com)

[www.bioinvent.com](http://www.bioinvent.com)

*Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 30 April 2012.*